Last checked at 17 Mar 2009 17:08
For release: 17 March 2009
Epistem Holdings Plc
Additional Listing
Epistem (AIM: EHP) announces that 10,000 new ordinary shares of 1.5 pence each (the "New Ordinary Shares") have been issued and allotted pursuant to the exercise of options under the Epistem Holdings Plc EMI Share Option Scheme.
Application has been made to the London Stock Exchange for the New Ordinary Shares to be admitted to trading on AIM. Admission is expected to be effective from 23 March 2009.
Following the admission to trading of the new ordinary shares, Epistem will have 7,211,083 ordinary shares of 1.5 pence each in issue.
For further information, please contact:
Matthew Walls +44 (0) 161 606 7258
CEO
Anna Dunphy / Mike Wort +44 (0) 207 861 3838
De Facto Communications
Notes to Editors:
Epistem is a biotechnology company commercialising its expertise in epithelial stem cells in the areas of oncology, gastrointestinal and dermatological diseases. Epistem develops innovative therapeutics and biomarkers and provides contract research services to drug development companies. The Group's expertise is focused on the regulation of adult stem cells located in epithelial tissue, which includes the gastrointestinal tract, skin, hair follicles, breast and prostate. Epistem does not conduct research in the areas of embryonic stem cells or stem cell transplantation.